Head-To-Head Contrast: CERo Therapeutics (CERO) vs. Its Competitors

CERo Therapeutics (NASDAQ:CERO) is one of 248 public companies in the “MED – DRUGS” industry, but how does it contrast to its rivals? We will compare CERo Therapeutics to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, risk and dividends.

Institutional and Insider Ownership

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 12.7% of CERo Therapeutics shares are owned by company insiders. Comparatively, 13.4% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares CERo Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CERo Therapeutics	N/A	-$8.30 million	0.00
CERo Therapeutics Competitors	$30.37 billion	$57.77 million	3.41

CERo Therapeutics’ rivals have higher revenue and earnings than CERo Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

CERo Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, CERo Therapeutics’ rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.

Profitability

This table compares CERo Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
CERo Therapeutics Competitors	-17,185.43%	-140.82%	-16.76%

Analyst Recommendations

This is a summary of current ratings and target prices for CERo Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	2	0	1	2.25
CERo Therapeutics Competitors	2039	3739	9775	399	2.53

CERo Therapeutics presently has a consensus target price of $45.00, indicating a potential upside of 65,117.39%. As a group, “MED – DRUGS” companies have a potential upside of 58.06%. Given CERo Therapeutics’ higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than its rivals.

Summary

CERo Therapeutics rivals beat CERo Therapeutics on 9 of the 13 factors compared.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.